Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this observational study publication.

Denosumab affects calcium and phosphate metabolism, especially in chronic kidney disease (CKD).

Levels were normalized by six months.

Who Took Part

The abstract describes 11,586 patients taking part.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

This retrospective observational study analyzed data from three Korean hospitals, including patients treated with denosumab between November 2016 and December 2021.

The researchers assessed the mean percentage change in serum phosphate, calcium, and PTH levels from baseline to 6 months post-treatment.

How the Study Was Run

Among the 11,586 patients, 10,069 had normal kidney function, while 1517 had CKD.

What Was Measured

Levels were normalized by six months.

The subject headings attached to it are Denosumab, Parathyroid Hormone, Renal Insufficiency, Chronic, Calcium, Bone Density Conservation Agents, Phosphates and Osteoporosis.

Author keywords: Chronic kidney disease.

What This Means in Plain Language

This is an observational study of Parathyroid Hormone (PTH 1-84) in 11,586 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.